Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilucoplan in Pediatric Generalized Myasthenia Gravis (ziMyG+)
NCT06435312Phase 3Enrolling by invitation
- Sponsor
- UCB
- Start
- Nov 2024
- Primary completion
- Oct 2027
- Modality
- Cyclic Peptides
- Countries
- 4
01
Overview
A Phase 3 trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Started Nov 2024; status: enrolling by invitation.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06435312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435312.